Abstract
Gene expression profile (GEP) is a commercially available blood test which is noninferior to endomyocardial biopsy in detecting rejections after orthotopic heart transplant (OHT). A reference value below 34 in patients (pts) at least 6 months post OHT is associated with a very low risk of rejection. The variability of serial GEP scores has been shown to independently predict future hemodynamic compromise or death. The purpose of this study is to characterize the within pt GEP score variability in a large population over 4 periods of time post OHT.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
